Physician profile
Paul E Berard
NPI 1699773804
$15,219.79
in general payments reported to CMS, 2019-2025
65 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,999 · 2020: $3,897 · 2021: $31.84 · 2022: $412 · 2023: $1,013 · 2024: $1,700 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,656 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.84 |
| Education | $224.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,433.95 | 2019-2020 | |
| Janssen Biotech, INC. | $898.40 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $877.55 | 2019-2025 | |
| Pfizer INC. | $802.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $801.71 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $794.23 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $747.38 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $665.17 | 2019-2025 | Blincyto, Kyprolis |
| Celgene Corporation | $658.26 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Abbvie INC. | $563.72 | 2019-2025 | |
| Genentech USA, INC. | $514.26 | 2019-2025 | Columvi, Lunsumio, Polivy |
| Astellas Pharma US INC | $496.45 | 2019-2023 | |
| Incyte Corporation | $419.22 | 2019-2025 | Jakafi, Zynyz, Jakafi |
| Genzyme Corporation | $400.97 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $357.80 | 2019-2024 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Berard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.